TNF inhibitors indicated for the treatment of rheumatoid arthritis, psoriasis and inflammatory bowel disease formed the largest share of the market, with the top three products: Remicade, Humira and Enbrel accounting for 40.1% of the market in 2010.

GSK and Human Genome Sciences' Benlysta was the first product to be approved for the treatment of systemic lupus erythematous in the past 30 years, a key step in the disease treatment. Benlysta will reach sales of $401m in 2016.

Your key questions answered

What are the current growth drivers in the global immunomodulator market?

What are the new therapeutic approaches in the immunomodulators market and which of these offer significant potential in the future?

What is the forecast commercial potential of the most promising compounds in clinical development?

Who are the leading players in each indication in the immunomodulators market, and what are their strategies?

How will the launch of late stage pipeline products and patent expires impact the market to 2016?